AYTU
AYTU BioPharma, Inc. Common Stock
stockNASDAQ
aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company's most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company's mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.83 | 2026-11-06 | -2.73% | -0.663 |
| 1M | 1.99 | 2026-10-13 | -10.55% | 0.618 |
| 3M | 2.30 | 2026-08-13 | -22.61% | 0.625 |
| 6M | 2.25 | 2026-05-13 | -20.89% | 0.590 |
| 1Y | 2.06 | 2025-11-13 | -13.59% | 0.712 |
| 2Y | 1.75 | 2024-11-13 | +2.01% | — |
| 5Y | 49.40 | 2021-11-12 | -96.40% | 0.853 |
AYTU BioPharma, Inc. Common Stock (NASDAQ:AYTU) stock price today is $1.78, and today's volume is 18,601. AYTU is down 0.559% today. The 30 day average volume is 25,444. AYTU market cap is $19.34M with 10.87M shares outstanding.